Doug Ingram, Sarepta Therapeutics CEO (Michael Nagle/Bloomberg via Getty Images)
June 4, 2025 03:49 PM EDT
Cell/Gene Tx
FDA+

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Lei Lei Wu

News Reporter

Sarep­ta Ther­a­peu­tics said Wednes­day it won “plat­form tech­nol­o­gy” sta­tus for one of its gene ther­a­py com­po­nents, mark­ing the first pub­lic dis­clo­sure …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

Oma­da Health is go­ing pub­lic on Fri­day at a $1.1B val­u­a­tion

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times